Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OCGN
OCUGEN, INC.
NASDAQ
$1.32
▼ DOWN 3.65% (-0.05)

KEY STATISTICS

Market Cap$447.63 M
52w High$2.73
52w Low$1.00
Dividend Yield—
Frequency—
P/E-5.08
Volume3.05M
Shares Out.339.11M

COMPANY

LEADERSHIP

Shankar Musunuri
CHIEF EXECUTIVE
Shankar Musunuri

COMPENSATION 2026

Salary$757,900
Stock Awards$520,492
Incentive Plan Pay$0
All Other Comp.$8,233
Total$1,941,538

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 3, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
116

PRICE TARGET

Target High$6.00
Target Low$3.50
Target Median$5.00
Target Consensus$5.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$1.08M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2019-09-30Reverse1:60

PRICE

$1.32 ▼ DOWN 3.65% (−$0.05)
OVERLAYS
$1.32$1.33$1.35$1.369:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.32

About Ocugen, Inc.

https://www.ocugen.com ↗

Ocugen, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for blindness and retinal diseases, with partnerships for co-development, manufacturing, and U.S. commercialization.

INDUSTRY

Biotechnology

A PRODUCT OCUGEN, INC. IS KNOWN FOR

OCU400
OCU400

OCU400 is Ocugen's lead gene therapy candidate for retinitis pigmentosa, in Phase 3 trials and expected for regulatory submission in the U.S. and Europe between 2026 and 2027.

COMPETITORS

COMPETITOR
MGTX COMPARE
REPL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
75
LISTED HERE
13
RANKED BY POSITION SIZE
XBI
0.17% · 14.9M
VTI
0.00% · 10.2M
IWM
0.01% · 8.6M
LABU
0.12% · 542.1K
XRSU.L
0.01% · 312.6K
RSSL
0.01% · 161.6K
ONEQ
0.00% · 133.0K
SILX
0.27% · 83.5K
GERM
0.76% · 56.6K
URTY
0.01% · 13.9K
PWS
0.04% · 6.5K
RESM
0.01% · 651
RTYS.L
0.02% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
41.16%
HOLDERS
214
TOP 12 OF 214 · RANKED BY POSITION SIZE
Blackrock, Inc.
27.0M sh · $41.31M
State Street Corp
21.5M sh · $32.85M
Blackrock Inc.
17.9M sh · $27.78M
Vanguard Group Inc
16.5M sh · $22.24M
Millennium Management LLC
13.9M sh · $21.33M
Geode Capital Management, LLC
8.9M sh · $13.58M
Marshall Wace, Llp
8.1M sh · $14.57M
Ubs Group AG
7.3M sh · $13.18M
Rtw Investments, LP
6.7M sh · $10.2M
Gmt Capital Corp
4.2M sh · $6.77M
Ikarian Capital, LLC
4.0M sh · $6.06M
Qube Research & Technologies Ltd
3.8M sh · $6.83M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Full)
2022-11-08
 Christopher L. Jacobs
Christopher L. Jacobs
Sale (Full)
2022-11-08

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Johnson-Greene Treerita Essalima
Purchase · 21.0K shares
2026-06-15
★
DIRECTOR
Kompella Uday
Purchase · 170.1K shares
2026-06-11
★
DIRECTOR
Chandrasekhar Satishchandran
Purchase · 170.1K shares
2026-06-11
★
DIRECTOR
Castillo Kirsten
Purchase · 170.1K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity BUY Chardan Capital BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ALMS$22.38COMPARE
OMER$18.61COMPARE
LXRX$2.29COMPARE
NGNE$36.58COMPARE
CMPX$2.40COMPARE
FULC$3.85COMPARE
NMRA$1.39COMPARE
ADCT$1.14COMPARE